Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

758 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, Sued O, Belonosova E, Ait-Khaled M, Angelis K, Brown D, Singh R, Talarico CL, Tenorio AR, Keegan MR, Aboud M; International Study of Patients with HIV on Rifampicin ING study group. Dooley KE, et al. Clin Infect Dis. 2020 Feb 3;70(4):549-556. doi: 10.1093/cid/ciz256. Clin Infect Dis. 2020. PMID: 30918967 Clinical Trial.
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
Haubrich R, Thompson M, Schooley R, Lang W, Stein A, Sereni D, van der Ende ME, Antunes F, Richman D, Pagano G, Kahl L, Fetter A, Brown DJ, Clumeck N. Haubrich R, et al. Among authors: brown dj. AIDS. 1999 Dec 3;13(17):2411-20. doi: 10.1097/00002030-199912030-00013. AIDS. 1999. PMID: 10597783 Clinical Trial.
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo JA, Mamedova E, Losso MH, Chetchotisakd P, Brites C, Sievers J, Brown D, Hopking J, Underwood M, Nascimento MC, Punekar Y, Gartland M, Smith K. Aboud M, et al. Lancet Infect Dis. 2019 Mar;19(3):253-264. doi: 10.1016/S1473-3099(19)30036-2. Epub 2019 Feb 4. Lancet Infect Dis. 2019. PMID: 30732940 Clinical Trial.
Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT.
Papot E, Jacoby S, Arlinda D, Avihingsanon A, Azwa I, Borok M, Brown D, Cissé M, Dao S, Eriobu N, Kaplan R, Karyana M, Kumarasamy N, Lee J, Losso MH, Matthews GV, Perelis L, Perez-Casas C, Ruxrungtham K, Watkins M, Lane HC, Kelleher A, Law M, Polizzotto MN; D2EFT Study Group. Papot E, et al. HIV Res Clin Pract. 2022 Jul 19;23(1):37-46. HIV Res Clin Pract. 2022. PMID: 35938597 Free PMC article. Clinical Trial.
758 results